Inactive Instrument

Analyst Reco. Amryt Pharma plc

Equities

HC Wainwright Downgrades Amryt Pharma to Neutral From Buy, Cuts Price Target to $14.50 From $18	18/23/18	MT
Maxim Group Downgrades Amryt Pharma to Hold From Buy	10/23/10	MT
Cantor Fitzgerald Downgrades Amryt Pharma to Neutral From Overweight, Adjusts Price Target to $14.75 From $25	10/23/10	MT
Canaccord Genuity Downgrades Amryt Pharma to Hold From Buy, Adjusts Price Target to $17 From $19	10/23/10	MT
Rate Hike Clues, China Border Reopening Fuel Gains for US Equity Futures	09/23/09	MT
Canaccord Genuity Assumes Amryt Pharma at Buy Rating With $19 Price Target	06/22/06	MT
SVB Securities Adjusts Amryt Pharma's Price Target to $19 From $18, Keeps Outperform Rating	24/22/24	MT
SVB Leerink Adjusts Amryt Pharma's Price Target to $18 from $10, Keeps Outperform Rating	05/22/05	MT
SVB Leerink Adjusts Amryt Pharma's Price Target to $10 from $9, Keeps Outperform Rating	10/22/10	MT
HC Wainwright Adjusts Amryt Pharma's Price Target to $18 From $20, Maintains Buy Rating	10/22/10	MT
HC Wainwright Adjusts Amryt Pharma's Price Target to $20 From $29, Reiterates Buy Rating	01/22/01	MT

No results for this search